Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032778 | 0.84 | — | — | |
| SCHEMBL22957177 | 0.81 | OXTR (0.38) | OXTRAVPR1ARAB9AKMT2APOLB | |
| SCHEMBL27625405 | 0.79 | CYP1A2 (0.44) | OXTRAVPR1ARAB9AKMT2AL3MBTL1 | |
| SCHEMBL9601697 | 0.78 | OXTR (0.40) | OXTRAVPR1ARAB9AKMT2APOLB | |
| SCHEMBL6413770 | 0.78 | — | — | |
| SCHEMBL26091092 | 0.75 | POLB (0.47) | OXTRAVPR1ARAB9AKMT2APOLB | |
| SCHEMBL12763786 | 0.73 | POLB (0.38) | OXTRAVPR1ARAB9AKMT2APOLB | |
| SCHEMBL19281353 | 0.73 | OXTR (0.38) | OXTRAVPR1ARAB9AKMT2APOLB | |
| SCHEMBL28701114 | 0.72 | CYP3A4 (0.48) | KMT2AL3MBTL1 | |
| SCHEMBL14937937 | 0.70 | KCNN1 (0.50) | RAB9AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033962-A1 | Tetracyclic indolopyridines as EG5 inhibitors | 4SC AG (DE) | 2009-03-11 | — | — | EP | claimed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | disclosed |
| US-9718809-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | disclosed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2033962-A1 | Tetracyclic indolopyridines as EG5 inhibitors | 4SC AG (DE) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | OXTR 4148/4885AVPR1A 3882/4885RAB9A 1664/4885 |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | OXTR 4145/4885AVPR1A 3921/4885RAB9A 1800/4885 |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | NFKBIA, IL6, LITAF | OXTR 4145/4885AVPR1A 3921/4885RAB9A 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.